Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma

被引：31

作者：

Oudard, Stephane ^{[1
]}

Medioni, Jacques ^{[1
]}

Aylllon, Jorge ^{[1
]}

Barrascourt, Eduardo ^{[1
]}

Elaidi, Reza-Thierry ^{[1
]}

Balcaceres, Jose ^{[1
]}

Scotte, Florian ^{[1
]}

机构：

[1] Paris Descartes Univ, Hop Georges Pompidou European Hosp, Dept Med Oncol, F-75015 Paris, France

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2009年 / 9卷 / 06期

关键词：

everolimus; metastatic renal cell carcinoma; mTOR inhibitor; progression-free survival; targeted therapy; PHASE-II TRIAL; INTERFERON-ALPHA; MAMMALIAN TARGET; NEUROENDOCRINE TUMORS; DOUBLE-BLIND; THERAPY; TEMSIROLIMUS; SUNITINIB; SORAFENIB; EFFICACY;

D O I：

10.1586/ERA.09.27

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recent introduction of drugs that inhibit angiogenesis or the mTOR has provided new options for the treatment of metastatic renal cell carcinoma, a disease which often has a poor prognosis. Chemotherapy and cytokine therapy are largely ineffective. The 5-year survival rate is under 10%. Everolimus, an immunosuppressive drug widely used for the prevention of allograft rejection and an mTOR inhibitor, is one of the latest drugs undergoing clinical trials in metastatic renal cell carcinoma. It has been tested in patients with progressive disease after therapy with tyrosine kinase receptor inhibitors (sunitinib, sorafenib or both), which interfere with signaling pathways, such as the VEGF pathway. Clinical efficacy results (progression-free survival) for everolimus are promising and the safety profile is good.

引用

页码：705 / 717

页数：13

共 51 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2] Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features [J].